Drugs A - Z

dantrolene Images

Generic Name: dantrolene

Brand Names: Revonto, Dantrium, Dantrolene Sodium, Ryanodex

There is an FDA Alert for this drug. Click here to view it.

    Hepatic Effects of Oral Dantrolene
  • Risk of developing potentially fatal, hepatic injury (e.g., hepatitis); should not be used for unlabeled indications.
  • Females, patients >35 years of age, and those receiving other drugs (especially estrogens) concomitantly are at greatest risk.
  • Risk of symptomatic hepatitis (fatal and nonfatal) may be dose dependent; incidence much higher at dosages ≥800 mg daily than at dosages ≤400 mg daily. Even intermittent, short courses at higher dosages associated with increased risk. Use lowest possible effective dose.
  • Overt hepatitis most frequently observed between 3rd and 12th month of therapy.
  • Frequently monitor hepatic function. (See Hepatic Effects under Cautions.)
  • If benefits are not evident within 45 days, discontinue therapy.

The Healthline Site, its content, such as text, graphics, images, search results, and other material contained on the Healthline Site ("Content"), its services, and any information or material posted on the Healthline Site by third parties are provided for informational purposes only. None of the foregoing is a substitute for professional medical advice, examination, diagnosis, or treatment. Always seek the advice of a physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Healthline Site. If you think you may have a medical emergency, call your doctor or 911 immediately. Please read the Terms of Service for more information regarding use of the Healthline Site.